Martijn R. Meijerink
Amsterdam University Medical Centers, Cancer Center Amsterdam
Papers
3
Total Citations
61
H-Index
2
About
Martijn R. Meijerink is a leading surgical oncologist whose research is redefining the standards of care for solid tumors, particularly in the liver and prostate. His work centers on minimally invasive, image-guided ablation techniques—such as thermal ablation and irreversible electroporation (IRE)—as alternatives to traditional radical surgery. Meijerink’s landmark contribution is the phase III COLLISION trial (2024, 47 citations), which directly compared surgery versus thermal ablation for small colorectal liver metastases, challenging the long-held primacy of resection with evidence of comparable oncologic outcomes and superior safety. In the groundbreaking IRE-IMMUNO study (2024, 13 citations), he demonstrated that IRE for localized prostate cancer not only destroys tumors but also downregulates immune suppression and induces systemic anti-tumor T-cell activation—a dual therapeutic effect absent in radical prostatectomy. His recent work (2025) on merging high-volume pancreatic surgery centers provides critical insights into volume-outcome relationships. With a growing citation impact, Meijerink is a pivotal figure driving the paradigm shift toward less invasive, immunologically active cancer treatments.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3Impact of Merging two high-volume Centers on Patient Outcome1 citations · 2025